Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07118449 · ClinicalTrials.gov registry record · Phase 2
Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG
A Phase 2 study, sponsored by XyloCor Therapeutics.
- Not yet
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
NCT07118449 is a Phase 2 study that has not yet begun recruiting, run by XyloCor Therapeutics. The registered enrollment target is 116 participants.
The verdict
NCT07118449, a Phase 2 study, has not yet begun recruiting, sponsored by XyloCor Therapeutics.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
Study Summary
This is a 26-week (with a 26-week extension) multicenter, randomized, double-blind, placebo-controlled Phase 2 study of XC001 versus placebo. Approximately 116 participants who have CAD and have been referred for revascularization by CABG and who have, according to assessment by stress imaging multiple myocardial segments that are substantially ischemic, and that are unlikely to be fully revascularized during CABG for technical reasons, including diffuse atherosclerosis, lack of conduits, or insufficient target vessels. Patients will be randomized in a 1:1 to XC001 or placebo injections during the final stages of the CABG procedure. Patients will have a baseline CMR at day 4-6 post CABG and additional assessments in the primary study period will be performed on Day 14, and Weeks 4, 12, and 26, (and during the extension period at 52 weeks).
Interventions
- DRUG XC001
- DRUG A195/placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2025-08-27 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07118449
The ClinicalTrials.gov registry entry for NCT07118449 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is XyloCor Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which XC001 is the first listed.
NCT07118449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07118449 about?
NCT07118449 is a clinical study titled "Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG". This is a 26-week (with a 26-week extension) multicenter, randomized, double-blind, placebo-controlled Phase 2 study of XC001 versus placebo. Approximately 116 participants who have CAD and have been referred for revascularization by CABG and who have, according to assessment by stress imaging multi...
What is the current status of trial NCT07118449?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2025-08-27. Estimated completion is 2027-06-30.
What interventions are being tested in trial NCT07118449?
The interventions under investigation include: XC001 (DRUG), A195/placebo (DRUG).
Who is sponsoring clinical trial NCT07118449?
This trial is sponsored by XyloCor Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.